StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Fennec Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Fennec Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2023 was 94.1%. For fiscal 2023 it was 94.1%, against 94.4% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 202394.1%−0.3
FY2022Dec 31, 202294.4%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 202393.0%–
Q3 FY2023Sep 30, 202394.9%–
Q2 FY2023Jun 30, 202395.5%–
Q1 FY2023Mar 31, 202394.3%–

More Fennec Pharmaceuticals figures

See a number that looks wrong?